Libera Bio has been selected by Sifted as one of its young companies to watch in cancer therapeutics
EVQLV and Libera Bio collaborate to develop and deliver novel antibodies to intracellular cancer targets
Libera Bio announced today that it has closed its Seed Round to advance its MPN Technology® into enabling studies and towards the clinic
Libera Bio featured in Nature journal for its technology enabling intracellular antibody delivery to unlock high-value targets
Libera Bio Job Offer: Drug Development Project Manager
Libera Bio Job Offer: Director of Finance & Administration (DAF)
Nowture has entered the capital of Libera Bio as lead investor
Libera Bio is one of the three 2021 Salisbury Award winners by the US NFCR
Nano-Oncologicals: A Tortoise Trail Reaching New Avenues
Libera Bio receives the BIOGA Award to the Best Biotech Business Idea 2020
Founder’s Stories: LiberaBio
Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
A multifunctional drug nanocarrier for efficient anticancer therapy
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!